Amido ether substituted imidazoquinolines

Details Amido ether substituted imidazoquinolines Amido ether substituted imidazoquinolines

2006-10-03

2006-10-03

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07115622

ABSTRACT:
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gester
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5693811 (1997-12-01), Lindstrom
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster et al.
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6518265 (2003-02-01), Kato et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6656938 (2003-12-01), Crooks et al.
patent: 6660735 (2003-12-01), Crooks et al.
patent: 6660747 (2003-12-01), Crooks et al.
patent: 6664260 (2003-12-01), Charles et al.
patent: 6664264 (2003-12-01), Dellaria et al.
patent: 6664265 (2003-12-01), Crooks et al.
patent: 6667312 (2003-12-01), Bonk et al.
patent: 6670372 (2003-12-01), Charles et al.
patent: 6677347 (2004-01-01), Crooks et al.
patent: 6677348 (2004-01-01), Heppner et al.
patent: 6677349 (2004-01-01), Griesgraber
patent: 6683088 (2004-01-01), Crooks et al.
patent: 6696465 (2004-02-01), Dellaria, Jr. et al.
patent: 6706728 (2004-03-01), Hedenstrom et al.
patent: 6743920 (2004-06-01), Lindstrom et al.
patent: 6756382 (2004-06-01), Coleman et al.
patent: 6797718 (2004-09-01), Dellaria et al.
patent: 6818650 (2004-11-01), Griesgraber
patent: 2002/0016332 (2002-02-01), Slade
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 2002/0110840 (2002-08-01), Tomai et al.
patent: 2003/0130299 (2003-07-01), Crooks et al.
patent: 2003/0133913 (2003-07-01), Tomai et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2003/0161797 (2003-08-01), Miller et al.
patent: 2003/0199538 (2003-10-01), Skwierczynski et al.
patent: 2004/0014779 (2004-01-01), Gorden et al.
patent: 2004/0091491 (2004-05-01), Kedl et al.
patent: 2004/0132079 (2004-07-01), Gupta et al.
patent: 2004/0141950 (2004-07-01), Noelle et al.
patent: 2004/0147543 (2004-07-01), Hays et al.
patent: 2004/0162309 (2004-08-01), Gorden et al.
patent: 2004/0171086 (2004-09-01), Fink et al.
patent: 2004/0175336 (2004-09-01), Egging et al.
patent: 2004/0176367 (2004-09-01), Griesgraber et al.
patent: 2004/0180919 (2004-09-01), Lee et al.
patent: 2004/0181130 (2004-09-01), Fox et al.
patent: 2004/0181211 (2004-09-01), Elliot et al.
patent: 2004/0191833 (2004-09-01), Fink et al.
patent: 2004/0192585 (2004-09-01), Fox et al.
patent: 2004/0197865 (2004-10-01), Gupta et al.
patent: 2004/0202720 (2004-10-01), Wightman et al.
patent: 2005/0054590 (2005-03-01), Averett
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/46194 (2002-08-01), None
patent: WO 02/102377 (2002-12-01), None
patent: WO 03/020889 (2003-03-01), None
patent: WO 03/043572 (2003-05-01), None
patent: WO 03/045391 (2003-06-01), None
patent: WO 03/097641 (2003-11-01), None
patent: WO 04/091500 (2004-10-01), None
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2. A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society,102, pp. 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay for Interferons in Micro-test Plates”,Biotechniques,Jun./Jul. 78, 1983.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology,vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem,15, pp. 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem.,11, pp. 87-92 (1968).
Baranov, et al.,Chem. Abs.85, 94362, (1976).
Berėnyi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem.,18, pp. 1537-1540 (1981).
Chollet, et al, “Development of a Topically Active Imiquimod Formulation”,Pharmaceutical Development and Technology,4(1), pp. 35-43 (1999).
Izumi, et al., “1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines”,Bioorganic&Medicinal Chemistry,11, pp. 2541-2550 (2003).
Sidky etal., “Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine”,Cancer Research,52, 3528-3533, Jul. 1, 1992.
R.L. Miller et al., “Imiquimod applied topically: a novel immune response modifier and new class of drug”,International Journal of Immunopharmacology,21, 1-14 (1999).
Karl R. Beutner, MD, et al., “Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream”,J.Am.Acad.Dermatol.,vol. 41, No. 6, 1002-1007 (Dec. 1999).
Davis et al., “Self-Administered Topical Imiquimod Treatment of Vulvar Intraepithelial Neoplasia”,Journal of Reproductive Medicine,vol. 45, No. 8, 619-623, (Aug. 2000).
Alexander Steinmann et al., “Topical Imiquimod Treatment of a Cutaneous Melanoma Mestasis”,J.Am.Acad.Dermatol.,Letters, 555-556 (Sep. 2000).
Sofina et al., “Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations”, NCI Monograph 55,NIH Publication No. 80-1933, pp. 76-78, (1980).
Strandtmann,J Med. Chem,10(6), pp. 1063-1065 (1967).
Delgado et al.,Wilson and Gisvold's Textboo of Organic Medicianal and Pharmaceutical Chemistry,9th Edition, pp. 30-31 (1991).

Affiliated with

Also associated with

Rating

Amido ether substituted imidazoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amido ether substituted imidazoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amido ether substituted imidazoquinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3663701